

Carbetapentane Tannate and Chlorpheniramine Tannate Tablets

Bill of Materials			
Scale (mg/tablet)	Item	Material Name	Quantity/1000 Tablets (g)
60.00	1	Carbetapentane tannate	60.00
5.00	2	Chlorpheniramine tannate	5.00
65.00	3	Starch	65.00
150.00	4	Methylcellulose	150.00
32.00	5	Polygalacturonic acid	32.00
65.00	6	Dibasic calcium phosphate dehydrate	65.00
25.00	7	Povidone	25.00
5.40	8	Talc	5.40
3.93	9	FD&C Red #40 Aluminum Lake 40%	3.93
1.00	10	D&C Blue #1 Aluminum Lake 29%	1.00
4.00	11	Magnesium stearate	4.00
qs	12	Alcohol denatured 190 proof	qs

Carbidopa and Levodopa Tablets Sinemet

The inactive ingredients are cellulose, magnesium stearate, and starch. Tablets Sinemet 10–100 and 25–250 also contain FD&C Blue No. 2. Tablets Sinemet 25–100 also contain D&C Yellow No. 10 and FD&C Yellow. Sinemet CR (carbidopa–levodopa) is a sustained-release combination of carbidopa and levodopa for the treatment of Parkinson's disease and syndrome. The inactive ingredients in Sinemet CR 50–200 are D&C Yellow No. 10, magnesium stearate, iron oxide, and

other ingredients. Inactive ingredients in Sinemet CR 25–100 are magnesium stearate, red ferric oxide, and others. The Sinemet CR tablet is a polymeric-based drug delivery system that controls the release of carbidopa and levodopa as it slowly erodes. Sinemet CR 25–100 is available to facilitate titration and as an alternative to the half-tablet of Sinemet CR 50–200.

Carbidopa and Levodopa Tablets

Bill of Materials			
Scale (mg/tablet)	Item	Material Name	Quantity/1000 Tablets (g)
25.00	1	Carbidopa	25.00
100.00	2	Levodopa	100.00
224.00	3	Microcrystalline cellulose (Avicel PH 101)	224.00
15.00	4	Croscarmellose sodium	15.00
3.00	5	Silicon dioxide colloidal	3.00
3.00	6	Magnesium stearate	3.00
50.00	7	Carbidopa	50.00
200.00	8	Levodopa	200.00
80.00	9	Methocel E4M premium CR	80.00
61.00	10	Microcrystalline cellulose	61.00
2.00	11	Silicon dioxide colloidal	2.00
2.00	12	Magnesium stearate	2.00

Manufacturing Directions

1. This is a bilayer or two-compartment tablet consisting of a core layer of sustained-release carbidopa–levodopa overcoated with a layer of immediate-release carbidopa–levodopa.
2. The core ingredients (items 7–10) are blended separately (as are the outer layer [items 1–4] ingredients), compressed to produce core tablets, and then overcoated with the compressed outer-layer blend using a suitable coating press.